M&A Deal Summary

Gilead Sciences Acquires Immunomedics

On September 13, 2020, Gilead Sciences acquired life science company Immunomedics for 21.0B USD

Acquisition Highlights
  • This is Gilead Sciences’ 19th transaction in the Life Science sector.
  • This is Gilead Sciences’ largest (disclosed) transaction.
  • This is Gilead Sciences’ 15th transaction in the United States.
  • This is Gilead Sciences’ 2nd transaction in New Jersey.

M&A Deal Summary
Date 2020-09-13
Target Immunomedics
Sector Life Science
Buyer(s) Gilead Sciences
Deal Type Add-on Acquisition
Deal Value 21.0B USD

Target

Immunomedics

Morris Plains, New Jersey, United States
Immunomedics is a next-generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers. The company’s proprietary ADC platform centers on using a novel linker that does not require an enzyme to release the payload to deliver an active drug inside the tumor cell and the tumor microenvironment, thereby producing a bystander effect. Trodelvy, the company’s lead ADC, is the first ADC the FDA has approved for the treatment of people with metastatic triple-negative breast cancer and is also the first FDA-approved anti-Trop-2 ADC. Immunomedics was formed in 1982 and is based in Morris Plains, New Jersey.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Gilead Sciences

Foster City, California, United States
Category Company
Founded 1987
Sector Life Science
Employees18,000
Revenue 27.1B USD (2023)
DESCRIPTION
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.
Entrance to Gilead Sciences' corporate headquarters in Foster City, California.

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead Sciences was founded in 1987 and is Based in Foster City, California.

DEAL STATS #
Overall 20 of 24
Sector (Life Science) 19 of 23
Type (Add-on Acquisition) 16 of 20
State (New Jersey) 2 of 2
Country (United States) 15 of 17
Year (2020) 4 of 5
Size (of disclosed) 1 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-07-21 Tizona Therapeutics

South San Francisco, California, United States

Tizona Therapeutics is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people with cancer. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Its novel pipeline includes the clinical-stage TTX-080, an anti-HLA-G antibody, and a rich preclinical portfolio. Tizona was formed in 2015 and is based in South San Francisco, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-10 MYR Pharmaceuticals

Bad Homburg, Germany

MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV). MYR Pharmaceuticals is based in Bad Homburg, Germany.

Buy €1.2B
Mergr

Product

Company

Legal